Achieve Life Sciences (NASDAQ:ACHV) is focused on the development and commercialization of therapies for smoking cessation and nicotine addiction. Its primary project revolves around Cytisinicline, a plant-based alkaloid with the potential to help people quit smoking. By aiming to address the global smoking health epidemic, Achieve Life Sciences is committed to improving overall health outcomes and reducing the burden of smoking-related diseases. Their objective is to provide effective, accessible treatment options that support individuals in their journey to quit smoking and combat nicotine dependence. Through their research and development efforts, Achieve Life Sciences strives to bring innovative solutions to the market, demonstrating their dedication to public health and wellness.